|
TWST: What is Medical Ventures?
Mr. Geyer: Medical Ventures is a cardiovascular and surgical medical devices
company. We started out about four or five years ago specializing in surgical
and tissue products made out of bovine pericardium, which is the tissue that
surrounds the heart of a cow. The technology was originally used for a heart
valve implant, and then we started to use it for other tissue applications.
Then, about three years ago, we acquired a catheter products company called
Angiometrx and their core technology called Metricath. That was our foray into
the interventional cardiology market. There, we see a significant opportunity
and potential going forward. So our focus is now both on our tissue product line
as well as on our catheter product line. TWST: Would you give us an idea of what the overall medical device area is
today, as far as the trends and the issues that the group is facing?
Mr. Geyer: Overall, the medical devices business is growing dramatically,
particularly in the cardiovascular area, where we're focused. You are now seeing
the first baby boomers hitting the age of 60, and a significant amount of
cardiovascular disease beginning to occur. Also, devices on the market today are
becoming less and less invasive to the body than previously. We have keyed into
that with our catheter product line. Our device, called Metricath, basically
helps doctors correctly determine the proper size of stent to put in when doing
an angioplasty to treat cardiovascular disease. Metricath also confirms that
those stents have been properly deployed. We see trends whereby clinicians are
moving toward less and less invasive procedures, and toward doing things more
cost effectively. As a result, there is a significant boom in that area of the
market and we expect that to continue in the coming years.
Tickers included in this excerpt: MEV:TSX.V
For more information call (212) 952 7433. The
Wall Street Transcript does not endorse any of the comments made by interviewees, and does
not make stock recommendations.
|
|
